For U.S. healthcare professionals only

ADVATE has health-related quality-of-life results1

ADVATE has shown clinically meaningful improvements in physical functioning, well-being, general health, and/or energy level, based on physical component score.†1-3

Bodily pain

Reduced levels of pain and improvements in the limitations of work due to pain.1,2

Role physical

Improvements in the ability to perform work or other daily activities.1,2

Physical functioning

Changes not observed in limitations to a range of minor and major physical activities.1,2

General health

Changes not observed in the views and expectations of overall health.1,2

Clinically meaningful changes were not seen in the mental health-related component score and subcategories of Mental Health, Role Emotional, Social Functioning, and Vitality.

Prophylaxis with ADVATE improved physical health-related quality of life compared with on-demand treatment1

After 12 months of prophylactic treatment, physical health-related quality of life improved in patients, mainly due to clinically meaningful improvements in1-3:

Bodily pain

The amount of pain experienced by a patient and how much pain interferes with normal work.

Role physical

The impact physical health can have on performing work or other daily activities.

Clinically meaningful changes were not seen in1:

Physical health

The physical health-related subcategories of General Health and Physical Functioning.

Mental Health

The mental health-related component score and subcategories of Mental Health, Role Emotional, Social Functioning, and Vitality.

Selected Important Risk Information

Warnings & Precautions

Neutralizing antibodies (inhibitors) have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs). Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration.

Please see additional detailed important risk information below.

After starting treatment, help patients stay the course with ADVATE
Download brochure
What ADVATE dosage is right for my patient?
Find their dose
myPKFiT® can help personalize prophylaxis
Learn more
  1. Advate. Prescribing information. Baxalta US Inc; 2018.
  2. Maruish ME, ed. User's Manual for the SF-36v2 Health Survey. 3rd ed. QualityMetric Incorporated; 2011.
  3. Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10(3):359-367. Published correction appears in J Thromb Haemost. 2012;10(6):1204.